Twelve deaths have been reported as part of an outbreak of Listeria monocytogenes infections linked to frozen supplemental shakes, the US Food and Drug Administration said Monday. At least 38 people in 21 states had been infected,

The U.S. FDA and the Centers for Disease Control and Prevention said on Monday the agencies were investigating a multi-state outbreak of listeria infections linked to frozen supplemental shakes manufactured by Prairie Farms Dairy Inc.

The outbreak has infected 38 individuals, 37 of whom have been hospitalized, and 12 who have died A listeria outbreak linked to recalled frozen shakes has left 12 people dead, according to the U.S. Food and Drug Administration (FDA).

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday.  Patrizia Cavazzoni was formerly director of

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing back an industry veteran to lead its regulatory and drug safety operations.

Pfizer (NYSE:PFE) has tapped Patrizia Cavazzoni, the former head of drug regulation at the FDA, as its new chief medical officer. Cavazzoni was most recently director of the Center for Drug Evaluation and Research (CDER) at the U.

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.